ORLANDO, FL, September 16, 2026 – NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussio
During a recent presentation, MAJI, a clinical-stage biotechnology company pioneering proprietary exosome-based delivery and diagnostic systems,referenced a study evaluating the anti-aging properties of Maxasome Plus in collaboration with Baylor University. MAJI clarified that while this initiative had not been previously announced, the Company and its partner, Xycota, are finalizing a Material Transfer Agreement.
MAJI also highlighted plans to expand its product offerings with the upcoming launch of a Maxasome Plus formulation specifically tailored for household pets. MAJI anticipates introducing this veterinary formulation as its third commercial product later this year.
Additionally, MAJI discussed recent developments regarding its international partnerships. Following productive discussions and contract renegotiations with its Japanese partner, MAJI equity ownership has increased from 70% to 75%. As a result of this renegotiation, an additional 11,277,000 shares of LMMY stock will be issued to MAJI.
Letter of Intent to Acquire 100% of Xycota Biosciences, LLC for Precision Neuro-Restoration with Exosome-Delivered Brain Circuitry Repair Platform
MAJI has executed a definitive Letter of Intent (LOI) to acquire 100% of Xycota Biosciences, LLC, a preclinical biotechnology platform engineering non-psychoactive, precision-targeted therapeutics to physically repair brain circuitry and restore synaptic connectivity.
Xycota is advancing a transformative biological interface designed to physically repair damaged neural networks in catastrophic neurodegenerative diseases. By utilizing proprietary fungal-derived exosome delivery systems, Xycota’s lead candidate, XYCO-01, directly upregulates the BDNF-TrkB neuroplasticity signaling pathway while bypassing first-pass liver metabolism and hallucinogenic receptor activation. This paradigm-shifting approach decouples therapeutic neural restoration from psychedelic side effects, establishing a standardized, controllable mechanism for structural brain repair. For more information, visit https://xycota.com/.
MAJI acquisition target Xycota has formally applied for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration (FDA) for XYCO-01 in its primary indication, Frontotemporal Dementia (FTD). Official issuance of the ODD status is expected shortly. Upon designation and approval, ODD status provides seven years of U.S. market exclusivity, tax credits for qualified clinical testing, and regulatory fee exemptions, greatly accelerating the clinical and commercial development roadmap.
Following the initial lead indication in Frontotemporal Dementia, the platform offers rapid expansion for MAJI into Amyotrophic Lateral Sclerosis (ALS), mild traumatic brain injury (mTBI), and broader neurodegenerative conditions.
“Executing this LOI to acquire 100% of Xycota Biosciences marks a defining milestone in NexTel Medical’s corporate development and growth trajectory,” stated Matthew Dwyer, President and Chief Executive Officer of MAJI. “Xycota’s cutting-edge exosome delivery platform addresses immense unmet clinical needs in Frontotemporal Dementia and ALS where no restorative therapies currently exist. Combining Xycota’s breakthrough neuro-restoration architecture with NexTel’s commercial infrastructure creates an extraordinary, value-generative catalyst for our shareholders.”
Advancing Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion Animals
MAJI has announced a major commercial expansion into veterinary oncology with the upcoming rollout of its novel cancer screening platform for household pets.
By expanding its proprietary technology into animal health, MAJI is poised to capture significant market share in the rapidly growing companion animal healthcare sector. MAJI will process all diagnostic samples centrally in its specialized laboratory, collaborating closely with veterinary oncologists nationwide to collect and screen blood samples against diverse cancer profiles.
Cancer remains the leading cause of disease-related death in companion animals, creating an urgent, unmet clinical demand for accessible, early-detection diagnostics.
Roughly 12 million dogs and cats are diagnosed with cancer in the United States every year.
Small domestic pets (including rabbits, ferrets, and rodents) experience disproportionately high tumor incidence rates, presenting further expansion potential.
The global veterinary oncology market is estimated at $2.0 billion to $2.9 billion annually. North America accounts for over 50% of total global spend, with domestic pet owners spending $1.0 billion to $1.4 billion annually on specialized oncology care and diagnostics.
By positioning its screening platform as a routine diagnostic tool for annual veterinary checkups, MAJI aims to establish a recurring, predictable revenue stream while significantly advancing standard-of-care practices in animal health.
Clinical-Stage Biotechnology Company Pioneering Proprietary Exosome-Based Delivery and Diagnostic Systems.
Equity Ownership of LMMY Increased from 70% to 75% with an Additional 11,277,000 Shares of LMMY Stock Issued to MAJI.
Plans to Acquire 100% of Xycota Biosciences, LLC for Precision Neuro-Restoration with Exosome-Delivered Brain Circuitry Repair Platform.
Xycota Biosciences has a Pending FDA Orphan Drug Designation.
Advancing Veterinary Oncology Strategy with Early-Stage Cancer Screening of Companion Animals.
Global Veterinary Oncology Market Estimated at $2.0 to $2.9 Billion Annually.
North America Accounts for Over 50% of Total Global Spend with $1.0 to $1.4 Billion Annually for Specialized Oncology Care and Diagnostics.
About NexTel Medical Corp. (OTCID Stock Symbol: MAJI)
NexTel Medical Corp. (OTC: MAJI) is a clinical-stage biotechnology and healthcare company focused on developing next-generation exosome-based delivery systems and diagnostic technologies, with an emphasis on potential applications in oncology and other areas of medicine. The company is working to combine biotechnology innovation with commercial healthcare opportunities, including proprietary exosome products, non-invasive diagnostic screening and strategic healthcare platforms.
Mission
NexTel’s mission is essentially to harness the potential of exosome technology to develop innovative therapeutic and diagnostic solutions. Its strategy is centered on using exosomes as biological delivery vehicles while developing technologies intended to provide more targeted and potentially less-invasive approaches to healthcare and disease detection.
When Was NexTel Incorporated?
The company was originally incorporated on April 28, 2010, in Nevada before becoming Exousia Pro, Inc. in 2025 and NexTel Medical Corp. on March 17, 2026. The company later redomiciled to Florida.
For more information on MAJI visit: www.nextelmedical.com
Email: ir@nextelmedical.com or msheikh@nextelmedical.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Media Contact
Company Name: NexTel Medical Corp. (Stock Symbol: MAJI)
Contact Person: Matthew Dwyer, President and CEO
Email: Send Email
Phone: +1 509-605-6533
Address:7901 4th Street N #23494 Saint Petersburg, FL 33702 United States
Country: United States
Website: www.nextelmedical.com
